Table 3.
Financial information concerning the various companies developing or commercializing GBM treatments, extracted from the 2017 annual report of these companies.
| Co name | Year founded | Location (HQ) 2016 | Revenue (MS, 2016) | Net income/Loss (MS, 2016) | Accumulated losses (MS) | No. of employees 2016 | R & D (% GBM) (MS, 2016) | Gal & Admin (MS, 2016) | Market value (MS, 2018) |
|---|---|---|---|---|---|---|---|---|---|
| Agenus | 1994 | Lexington (USA) | 22 | −127 | 905 | 255 | 94 (8% GBM) | 33 | 516 |
| Celldex | 2005 | Hampton (USA) | 7 | −128 | 719 | 210 | 103 (10% GBM) | 36 | 317 |
| CytRx | 1985 | San Francisco (USA) | 0.2 | −51 | 416 | 27 | 36 (<10% GBM) | 16 | 243 |
| Deciphera Pharma | 2003 | Waltham (USA) | 0 | −12 | 176 | 42 | 14 (<15% GBM) | 4 | 57 |
| DelMar Pharma | 2009 | Vancouver (Canada) | 0 | −9 | 41 | 4 | 5 (100% GBM) | 3 | 23 |
| Elekta | 1972 | Stockholm (Sweden) | 11 | 0.1 | N.A. | 3,600 | 0.15 (>50% GBM) | 0.09 | N.A. |
| Immuno-cellular | 1987 | Los Angeles (USA) | 0 | −27 | 96 | 7 | 19 (100% GBM) | 5 | 4.2 |
| Midatech | 2000 | Oxford (UK) | 6.4 | −20 | 59 | 84 | 6.7 (15–30%) | 9 | 22 |
| Northwest biotherapeutics | 1996 | Bethesda (USA) | 0.6 | −80 | 715 | 15 | 60 (100% GBM) | 11 | N.A. |
| Novocure | 2000 | Jersey Isle | 83 | −131 | 520 | 450 | 41 (20% GBM) | 51 | N.A. |
| Noxxon | 1997 | Berlin (Germany) | 0.083 | −11 | 129 | 10 | 5 (<20% GBM) | 4 | 12.3 |
| Roche | 1896 | Basel (Switzerland) | 54,000 | 8,825 | NA | 94,000 | 10,400 (<5% GBM) | NA | 190,988 |
| Tocagen | 2007 | San Diego (USA) | 0.031 | −28 | 156 | 61 | 21 (100% GBM) | 6 | 215 |
The year of creation of these companies, the location of their headquarter, their revenues in 2016, their net incomes or losses in 2016, their accumulated losses since their foundation, their number of employees in 2016, their amount of spending in R&D in 2016 with the estimated percentage of this spending dedicated to GBM research, their administrative and general spending in 2016, as well as the market value of these companies in 2016, are indicated. The market value was estimated by multiplying the value of the share by the number of shares for each of these companies. The percentage of R&D spending dedicated to GBM research was estimated by dividing the number of GBM drugs by the total number of drugs developed/commercialized by each of these companies. This estimate relies on the analysis of the 2017 annual report of these companies, possibly not mentioning some drug developments, hence possibly leading to overestimate/underestimate of this percentage.